Liste des publications

Rita Tanos, Alain R. Thierry. Clinical relevance of liquid biopsy for cancer screening. Transl Cancer Res 2018;7(Suppl 2):S105-S129


Jeitany M, Leroy C, Tosti P, Lafitte M, Le Guet J, Simon V, Bonenfant D, Robert B, Grillet F, Mollevi C, El Messaoudi S, Otandault A, Canterel-Thouennon L, Busson M, Thierry AR, Martineau P, Pannequin J, Roche S, Sirvent A. Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018 Feb 9. pii: e7918. doi: 10.15252/emmm.201707918. [Epub ahead of print]


Prévostel C, Blache P. The dose-dependent effect of SOX9 and its incidence in colorectal cancer. Eur J Cancer. 2017 Oct 5;86:150-157


Barbieri A, Peyhardi J, Conroy T, Gourgou S, Lavergne C, Mollevi C. Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials. BMC Med Res Methodol. 2017 Sep 26;17(1):148. doi: 10.1186/s12874-017-0410-9.


Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/ annonc/mdx330.


Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, Zghaib Z, Khier S, Deleuze-Masquefa C, Gattacceca F. Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS One. 2017 Aug 10;12(8):e0182022. doi: 10.1371/ journal.pone.0182022. eCollection 2017.


Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017 Aug 19;84:239-249. doi: 10.1016/j.ejca.2017.07.038. [Epub ahead of print]


A.R. Thierry, S. El Messaoudi, C. Mollevi, J.L. Raoul, R. Guimbaud, D. Pezet, P. Artru, E. Assenat, C. Borg, M. Mathonnet. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Ann Oncol mdx330. DOI:


Parseghian C, Parikh NU, Wu JY, Jiang ZQ, Henderson LD, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman D, Katsiampoura A, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Mar 9. pii: clincanres.3138.2016. doi: 10.1158/1078-0432.CCR-16-3138. [Epub ahead of print]


Alain R. Thierry, Brice Pastor, Zhi-Qin Jiang, Anastasia Katsiampoura, Christine Parseghian, Jonathan M. Loree, Michael J. Overman, Cynthia Sanchez, Safia El Messaoudi, Marc Ychou and Scott Kopetz. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clinical Cancer Research, 10.1158/1078-0432.CCR-17-0232


Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L. Population pharmacokinetics of gemcitabine and dFdU in pancreatic cancer patients using an optimal design, sparse sampling approach. Ther Drug Monit. 2017 Mar 24. doi: 10.1097/FTD.399. [Epub ahead of print] PubMed PMID: 28346313.


Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017 Mar 8;76:68-75. doi: 10.1016/j.ejca.2017.02.003. [Epub ahead of print]


Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016 Jul 8. [Epub ahead of print]


Prévostel C, Rammah-Bouazza C, Trauchessec H, Canterel-Thouennon L, Busson M, Ychou M, Blache P. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ß-catenin signaling. Oncotarget. 2016 Jul 13. [Epub ahead of print]


Boissière-Michot F, Frugier H, Ho-Pun-Cheung A, Lopez-Crapez E, Duffour J, Bibeau F. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. Virchows Arch. 2016 May 25. [Epub ahead of print]


Nascimento AV, Gattacceca F, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models. Nanomedicine (Lond). 2016 Apr;11(7):767-81.  Epub 2016 Mar 16. 


Thierry AR. A Targeted Q-PCR - Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care. Methods Mol Biol. 2016; 1392: 1-16. doi: 10.1007/978-1-4 939- 3360-0_1.



El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet CG, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR. Circulating DNA as a strong multi-marker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 2016 Feb 4. [Epub ahead of print]


Barbieri A, Anota A, Conroy T, Gourgou-Bourgade S, Juzyna B, Bonnetain F, Lavergne C, Bascoul-Mollevi C. Applying the Longitudinal Model from Item Response Theory to Assess the Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial. Med Decis Making. 2015 Dec 18. pii: 0272989X15621883. [Epub ahead of print]


Duffour J, Combes A, Crapez E, Boissière-Michot F, Bibeau F, Senesse P, Ychou M, Courraud J, de Forges H, Roca L. Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options. J Genet Couns. 2015 Sep 22. [Epub ahead of print]


Colombo PE, du Manoir S, Orsetti B, Bras-Gonçalves R, Lambros MB, MacKay A, Nguyen TT, Boissière F, Pourquier D, Bibeau F, Reis-Filho JS, Theillet C. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.
Oncotarget. 2015 Sep 29;6(29) :28327-40.


Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug;16(8):937-48. Epub 2015 Jul 13.


Guimbaud R, Louvet C, Ychou M, Bouché O, Rougier P. Reply to E.C. Smyth et al and E. Elimova et al.
J Clin Oncol. 2015 Jun 15. pii: JCO.2014.60.5550. [Epub ahead of print]


Delbaldo C, Ychou M, Zawadi A, Douillard JY, André T, Guerin-Meyer V, Rougier P, Dupuis O, Faroux R, Jouhaud A, Quinaux E, Buyse M, Piedbois P; AERO, GERCOR, FNLCC and FFCD.
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†. Ann Oncol. 2015 Jun;26(6): 1208-15. Epub 2015 Mar 3.


Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, Del Conte G, Durigova A, Hayaoui N, Gourgou S, Gianni L, Mollevi C. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. J Clin Oncol. 2015 May 26. pii: JCO.2014.58.1082. [Epub ahead of print]


Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial. Oncotarget. 2015 May 20;6(14):12796-808.


Yadav S, Gattacceca F, Panicucci R, Amiji MM. Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation. Mol Pharm. 2015 May 4;12(5):1523-33. doi: 10.1021/ mp5008376. Epub 2015 Mar 31


Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C.
Establishment and characterization of a cell line from human circulating colon cancer cells.
Cancer Res. 2015 Mar 1;75(5):892-901. Epub 2015 Jan 15.


Lopez-Crapez E, Ho-Pun-Cheung A, Garnero P, Bazin H. Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET). Methods Mol Biol. 2015;1233:45-55. doi: 10.1007/978- 1-4939-1789-1_5.


Mouliere F, El Messaoudi 1, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell- free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014 Mar 24. pii: S1574- 7891(14)00041-6. doi: 10.1016/j. molonc. 2014.02.005. [Epub ahead of print]


Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Mar 23. doi: 10.1038/nm.3511. [Epub ahead of print]


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés